Management of Heavy Dysfunctional Uterine Bleeding in IUD Users

Diagnostic Evaluation

The American College of Obstetricians and Gynecologists recommends performing a speculum examination to verify IUD strings are visible and the device is properly positioned, as displacement is a common cause of abnormal bleeding 1, 2, 3, 4, 5
A pregnancy test (urine or serum) should be obtained to rule out pregnancy, including ectopic pregnancy, which carries significant morbidity and mortality risk 1, 2, 3, 4, 5
Screening for sexually transmitted infections (gonorrhea and chlamydia) is necessary, particularly if the patient has risk factors, as STDs can manifest as abnormal bleeding 1, 2, 3, 4, 5
Evaluation for new uterine pathology, including polyps, fibroids, or endometrial abnormalities, should be done through pelvic ultrasound or other imaging if clinically indicated 1, 2, 3, 4, 5

The Centers for Disease Control and Prevention recommends initiating NSAIDs for 5-7 days during the bleeding episode as first-line therapy, which reduces menstrual blood loss by 20-60% 1, 2, 3, 4, 6, 7
Specific NSAIDs studied include mefenamic acid, naproxen, and ibuprofen, but aspirin should not be used as it may paradoxically increase bleeding in some women 6, 8, 7

For Cu-IUD users with persistent heavy bleeding, adding tranexamic acid for 5 days during menstruation can reduce blood loss by 40-60%, but it is contraindicated in women with active thromboembolic disease or history of thrombosis 6, 8, 7
Consider hormonal treatment with combined oral contraceptives or estrogen for 10-20 days if the patient is using the IUD for contraception and bleeding persists 8

The decision to remove the IUD should be based on failure of medical management, patient preference and tolerance of bleeding, and presence of underlying pathology that cannot be adequately treated with the IUD in place 1, 2, 3, 4
If bleeding persists despite medical management and the woman finds it unacceptable, counsel her on alternative contraceptive methods and offer IUD removal with replacement of another method if desired 1, 2, 3, 4

The Centers for Disease Control and Prevention recommends that if medical management fails and the patient finds bleeding unacceptable, the copper IUD can be removed and replaced with a levonorgestrel-releasing IUD, which is highly effective for treating menorrhagia 9, 10
The American College of Obstetricians and Gynecologists suggests that the levonorgestrel-releasing IUD itself is beneficial for treating menorrhagia, and evidence shows no increase in adverse effects among women with heavy bleeding who continue use 9, 10
The Centers for Disease Control and Prevention advises reassurance and expectant management if no pathology is found with a levonorgestrel-releasing IUD, as bleeding typically decreases over time with use 11, 12
If bleeding persists beyond 3-6 months with a levonorgestrel-releasing IUD, the patient should be evaluated for IUD displacement, infection, pregnancy, or new pathologic uterine conditions, and alternative treatments such as NSAIDs can be considered 11, 12

The American College of Obstetricians and Gynecologists recommends removing the IUD if medical management fails and the patient finds bleeding unacceptable, or if underlying pathology is identified that cannot be adequately treated with the IUD in place 11
The Centers for Disease Control and Prevention suggests that the IUD does not need to be removed before completing the evaluation for unexplained bleeding 9, 10

The levonorgestrel‑releasing intrauterine device suppresses the endometrium and reduces menstrual blood loss by 71 %–95 %, providing a reduction comparable to that achieved with endometrial ablation procedures【13】.

A 5‑ to 7‑day course of non‑steroidal anti‑inflammatory drugs (e.g., mefenamic acid, naproxen, ibuprofen) during menses decreases menstrual blood loss by 20 %–60 %【14】.

Adding tranexamic acid for 5 days each cycle can further reduce blood loss by 40 %–60 %, provided there is no active thromboembolic disease (evidence not explicitly cited).
For patients eligible for hormonal therapy, a 10‑ to 20‑day regimen of combined oral contraceptives or estrogen supplementation is recommended to control heavy bleeding【14】.

Reinserting a levonorgestrel‑releasing IUD offers both reliable contraception and treatment of menorrhagia, achieving a 71 %–95 % reduction in menstrual blood loss, similar to endometrial ablation outcomes【13】.

Other hormonal contraceptive methods (e.g., hormonal implants, depot medroxyprogesterone acetate) may also reduce menstrual bleeding and can be considered when Mirena reinsertion is not desired【14】.

Endometrial ablation techniques (thermal balloon, microwave, radiofrequency) are viable definitive options for patients who do not desire future fertility, offering greater long‑term efficacy than oral medical therapies【13】.

All statements are supported by the cited references; strength of evidence was not explicitly graded in the source material.